172 related articles for article (PubMed ID: 23007682)
1. Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.
Tsuji I; Sato S; Otake K; Watanabe T; Kamada H; Kurokawa T
MAbs; 2012; 4(6):732-9. PubMed ID: 23007682
[TBL] [Abstract][Full Text] [Related]
2. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
Sato S; Drake AW; Tsuji I; Fan J
PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a Novel Anti-Human HB-EGF Monoclonal Antibody Applicable for Paraffin-Embedded Tissues and Diagnosis of HB-EGF-Related Cancers.
Iwamoto R; Takagi M; Akatsuka J; Ono K; Kishi Y; Mekada E
Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):73-82. PubMed ID: 26974561
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effects of anti-human HB-EGF neutralizing polyclonal antibodies in vitro.
Siromolot AA; Krynina OI; Kolybo DV; Komisarenko SV
Exp Oncol; 2020 Mar; 42(1):25-30. PubMed ID: 32231194
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
6. Anti-human HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HB-EGF and diphtheria toxin binding.
Hamaoka M; Chinen I; Murata T; Takashima S; Iwamoto R; Mekada E
J Biochem; 2010 Jul; 148(1):55-69. PubMed ID: 20332144
[TBL] [Abstract][Full Text] [Related]
7. Ectodomain shedding of HB-EGF: a potential target for cancer therapy.
Miyazono K
J Biochem; 2012 Jan; 151(1):1-3. PubMed ID: 21976708
[TBL] [Abstract][Full Text] [Related]
8. Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.
Kasai N; Yoshikawa Y; Enokizono J
MAbs; 2014; 6(5):1220-8. PubMed ID: 25517307
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis.
Khong TF; Fraser S; Katerelos M; Paizis K; Hill PA; Power DA
Kidney Int; 2000 Sep; 58(3):1098-107. PubMed ID: 10972674
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4).
Chen C; Patel S; Corisdeo S; Liu X; Micolochick H; Xue J; Yang Q; Lei Y; Wang B; Soltis D
Hybridoma (Larchmt); 2005 Jun; 24(3):152-9. PubMed ID: 15943563
[TBL] [Abstract][Full Text] [Related]
11. Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line.
Miyoshi E; Higashiyama S; Nakagawa T; Hayashi N; Taniguchi N
J Biol Chem; 1997 May; 272(22):14349-55. PubMed ID: 9162071
[TBL] [Abstract][Full Text] [Related]
12. Vanadium stimulates human bronchial epithelial cells to produce heparin-binding epidermal growth factor-like growth factor: a mitogen for lung fibroblasts.
Zhang L; Rice AB; Adler K; Sannes P; Martin L; Gladwell W; Koo JS; Gray TE; Bonner JC
Am J Respir Cell Mol Biol; 2001 Feb; 24(2):123-31. PubMed ID: 11159045
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
Modjtahedi H; Komurasaki T; Toyoda H; Dean C
Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
[TBL] [Abstract][Full Text] [Related]
14. Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor.
Iwamoto R; Handa K; Mekada E
J Biol Chem; 1999 Sep; 274(36):25906-12. PubMed ID: 10464334
[TBL] [Abstract][Full Text] [Related]
15. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
Modjtahedi H; Dean C
Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
[TBL] [Abstract][Full Text] [Related]
16. Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody.
Sato S; Kamada H; Watanabe T; Tsuji I; Fan J
PLoS One; 2013; 8(1):e54509. PubMed ID: 23349913
[TBL] [Abstract][Full Text] [Related]
17. Transactivation of epidermal growth factor receptor after heparin-binding epidermal growth factor-like growth factor shedding in the migration of prostate cancer cells promoted by bombesin.
Madarame J; Higashiyama S; Kiyota H; Madachi A; Toki F; Shimomura T; Tani N; Oishi Y; Matsuura N
Prostate; 2003 Nov; 57(3):187-95. PubMed ID: 14518027
[TBL] [Abstract][Full Text] [Related]
18. Involvement of heparin-binding EGF-like growth factor and its processing by metalloproteinases in early epithelial morphogenesis of the submandibular gland.
Umeda Y; Miyazaki Y; Shiinoki H; Higashiyama S; Nakanishi Y; Hieda Y
Dev Biol; 2001 Sep; 237(1):202-11. PubMed ID: 11518516
[TBL] [Abstract][Full Text] [Related]
19. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein.
Higashiyama S; Lau K; Besner GE; Abraham JA; Klagsbrun M
J Biol Chem; 1992 Mar; 267(9):6205-12. PubMed ID: 1556128
[TBL] [Abstract][Full Text] [Related]
20. Soluble form of heparin-binding EGF-like growth factor contributes to retinoic acid-induced epidermal hyperplasia.
Kimura R; Iwamoto R; Mekada E
Cell Struct Funct; 2005; 30(2):35-42. PubMed ID: 16357442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
